Combination Study of BMS-754807 and Herceptin® in Patients With Advanced or Metastatic Her-2-positive Breast Cancer

NCT00788333 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: BMS-754807
DRUG: trastuzumab (Herceptin®)

Sponsor

Bristol-Myers Squibb